Neuren Pharmaceuticals Ltd (ASX: NEU) — Healthcare · Share Price, Chart & Market Data
About: Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: A$12.20 (-1.05%)
NEUNeuren Pharmaceuticals Ltd
Loading watchlist status…
Trade NEU now
Neuren Pharmaceuticals Ltd share price
NEU price activity
Last Price
Change (24hr)
AUD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 8:53 am GMT+0
NEU price performance
-2.322%
5D
7.965%
1M
-35.484%
YTD
7.584%
1Y
NEU price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
ASX rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 8:53 am GMT+0
NEU details
NEU Market Signals